Venture funding for women’s health in the US and Europe ended 2025 at $1.58 billion, following a spike in 2024, according to SVB’s analysis of the sector.
The 2026 rebound has been fast and concentrated. By March, two healthtech companies, Midi Health and Pomelo Care, had together raised more than half of 2025’s entire women’s healthtech total, and both reached unicorn status. Hot Investments: Where VC and PE Firms Are Investing in Women’s Health This Year covers where firms are placing bets by category. A related question for women’s health companies and their marketers is what those concentrated bets reward.
Where the Capital Is Going
The pattern points toward commercial proof. SVB highlights Midi as an example: the company began tracking its impact across clinical metrics and marketed its clinical and financial ROI to payers and employers. That move from product story to documented return produces evidence that holds up in a sales conversation and a diligence process alike.
The same logic shows up on the exit side. Blackstone and TPG completed their acquisition of Hologic in April 2026. Part of the price came as a contingent value right of up to $3 per share, paid based on whether Hologic’s Breast Health business hits global revenue goals in fiscal years 2026 and 2027, according to Hologic. That structure signals that the acquirers wanted revenue performance proven before paying the full price.
Broader digital health data shows the same concentration. Across the sector, companies raised $7.4 billion in the first half of 2026, and mega deals of $100 million or more absorbed 45% of that capital from just over 8% of transactions, according to Rock Health. Capital is available, and it is concentrated in a small number of companies.
What This Means for Vendor Positioning
Investors and healthcare buyers are converging on the same question. Rock Health reports that with AI now standard across digital health, the question both groups ask has become who has something AI alone can’t provide. The same report notes that the growing number of options has pushed buyer expectations for measurable ROI higher and made failed rollouts harder to tolerate.
For women’s health companies, that convergence simplifies the marketing brief. The outcomes data and customer references that persuade a benefits leader or health plan executive are the same materials that support a funding round. A company that treats buyer proof and investor proof as separate workstreams ends up doing the work twice.
Marketing Proof That Works for Buyers and Investors
Marketing can shorten the time it takes to build that proof. Outcomes content written in each buyer’s own metrics turns early contracts into evidence that travels, whether the audience is a benefits committee or an investment committee.
Partnerships add a second layer of credibility. Rock Health notes that aligning with organizations buyers already trust lowers the perceived risk of a new product, and each trusted relationship makes the next customer easier to win. Its examples include OpenEvidence’s collaboration with the American College of Obstetricians and Gynecologists, a women’s health case of a professional society lending its credibility to a technology partner. Co-authored content and joint webinars keep those partnerships visible across a buying process that averages 22 touchpoints and can take more than a year to close.
Where This Leaves the Market
Women’s health investment is growing again, and the clearest signals point toward companies that can document their value to the organizations that pay for it. The marketing that wins contracts and the marketing that supports a raise now draw on the same evidence. Companies that build it once, and build it deliberately, will be positioned for both.
